Nobilis Health Corp.
NRTSF · OTC
12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.74 | -0.28 | 0.01 | 0.08 |
| FCF Yield | 20.21% | -2.48% | 1.24% | 1.43% |
| EV / EBITDA | 6.41 | 11.48 | 6.00 | 6.95 |
| Quality | ||||
| ROIC | 2.78% | 2.51% | 25.26% | 8.18% |
| Gross Margin | 62.40% | 61.58% | 65.88% | 72.36% |
| Cash Conversion Ratio | 2.57 | 0.22 | 0.11 | 0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.35% | 50.38% | 94.55% | 59.02% |
| Free Cash Flow Growth | 633.35% | -270.54% | 17.34% | -13.78% |
| Safety | ||||
| Net Debt / EBITDA | 3.34 | 3.11 | 0.80 | 0.61 |
| Interest Coverage | 3.71 | 2.51 | 19.82 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 33.58 | 24.57 | 17.41 | 16.45 |
| Cash Conversion Cycle | 108.12 | 100.71 | 59.26 | 39.95 |